• +1-646-491-9876
    • +91-20-67278686

    Search

    Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Pipeline Review, H2 2016

    Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Pipeline Review, H2 2016

    • Report Code ID: RW0001499778
    • Category Pharmaceuticals
    • No. of Pages 81
    • Publication Month Nov-16
    • Publisher Name Global Markets Direct
    Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Pipeline Review, H2 2016

    Summary

    Publisher's, 'Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Pipeline Review, H2 2016', provides in depth analysis on Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted pipeline therapeutics.

    The report provides comprehensive information on the Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics development and features dormant and discontinued projects.

    Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

    Note:
    *Certain sections in the report may be removed or altered based on the availability and relevance of data.
    *Updated report will be delivered in 48 hours of order confirmation.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4)
    - The report reviews Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents

    List of Tables 4
    List of Figures 5
    Introduction 6
    Publisher Report Coverage 6
    Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) Overview 7
    Therapeutics Development 8
    Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Products under Development by Stage of Development 8
    Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Products under Development by Therapy Area 9
    Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Products under Development by Indication 10
    Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Pipeline Products Glance 12
    Late Stage Products 12
    Early Stage Products 13
    Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Products under Development by Companies 14
    Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Therapeutics Assessment 17
    Assessment by Monotherapy/Combination Products 17
    Assessment by Mechanism of Action 18
    Assessment by Route of Administration 20
    Assessment by Molecule Type 22
    Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Companies Involved in Therapeutics Development 24
    Antisense Therapeutics Limited 24
    Atox Bio Ltd. 25
    Biogen Inc 26
    BioMAS Ltd. 27
    Daiichi Sankyo Company, Limited 28
    EA Pharma Co Ltd 29
    Protagonist Therapeutics Inc. 30
    Takeda Pharmaceutical Company Limited 31
    Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Drug Profiles 32
    AB-103 - Drug Profile 32
    Product Description 32
    Mechanism Of Action 32
    R&D Progress 32
    ATL-1102 - Drug Profile 35
    Product Description 35
    Mechanism Of Action 35
    R&D Progress 35
    carotegrast - Drug Profile 40
    Product Description 40
    Mechanism Of Action 40
    R&D Progress 40
    CB-0602 - Drug Profile 42
    Product Description 42
    Mechanism Of Action 42
    R&D Progress 42
    natalizumab - Drug Profile 44
    Product Description 44
    Mechanism Of Action 44
    R&D Progress 44
    PTG-100 - Drug Profile 48
    Product Description 48
    Mechanism Of Action 48
    R&D Progress 48
    Small Molecule to Antagonize Integrin Alpha4 and Beta7 for Inflammatory Bowel Disease - Drug Profile 50
    Product Description 50
    Mechanism Of Action 50
    R&D Progress 50
    Small Molecule to Antagonize VLA-4 for Asthma - Drug Profile 51
    Product Description 51
    Mechanism Of Action 51
    R&D Progress 51
    Small Molecules to Antagonize Integrin Alpha 4 and Beta 2 for Autoimmune Disorders - Drug Profile 52
    Product Description 52
    Mechanism Of Action 52
    R&D Progress 52
    Small Molecules to Antagonize Integrin Alpha 4 and Integrin Beta 7 for Crohn's Disease and Ulcerative Colitis - Drug Profile 53
    Product Description 53
    Mechanism Of Action 53
    R&D Progress 53
    vedolizumab - Drug Profile 54
    Product Description 54
    Mechanism Of Action 54
    R&D Progress 54
    Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Dormant Projects 60
    Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Discontinued Products 65
    Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Featured News & Press Releases 66
    Oct 17, 2016: Takeda Presents Real-World Vedolizumab Data in Ulcerative Colitis and Crohn's Disease at 2016 American College of Gastroenterology (ACG) Annual Scientific Meeting 66
    Oct 17, 2016: Takeda's Vedolizumab Demonstrated Robust Clinical Effectiveness and Safety in Inflammatory Bowel Disease in More Than 50 Real-World Studies 67
    Oct 13, 2016: Scientists at NIH and Emory achieve sustained SIV remission in monkeys 68
    Oct 13, 2016: Protagonist Therapeutics to Present Phase 1 Clinical and Preclinical Data on PTG-100 at UEG Week, Vienna 70
    Oct 12, 2016: PROMETHEUS Anser VDZ Test Validated For Use in Inflammatory Bowel Disease Patients 70
    Sep 28, 2016: Additional Interim Data Supporting Long-Term Use of Vedolizumab in Patients with Ulcerative Colitis and Crohn's Disease Published in Journal of Crohn's and Colitis 71
    Sep 16, 2016: Favorable Benefit: Risk Profile for Vedolizumab as Induction and Maintenance Therapy in TNF-Naïve or TNF-Failure Patients with Moderately to Severely Active Ulcerative Colitis Published in Clinical Gastroenterology and Hepatology 72
    Sep 08, 2016: Biogen Presents Data on TYSABRI at the 32nd congress of the European Committee for Treatment and Research in Multiple Sclerosis 74
    Jun 17, 2016: Antisense Therapeutics provides update on ATL1102 for Multiple Sclerosis 75
    Jun 15, 2016: Atox Bio Awarded Next Milestone-based Option by BARDA to Support Development of AB103 for Necrotizing Soft Tissue Infections 76
    Jun 01, 2016: Antisense provides update on ATL1102 clinical trials 76
    May 31, 2016: Biogen Receives Positive CHMP Opinion for TYSABRI (Natalizumab) Use in Highly Active RRMS Patients with Inadequate Response to Prior MS Therapy 77
    May 26, 2016: Elan Pharma International Withdraw an application for a change to the marketing authorisation for Tysabri (natalizumab) 78
    May 24, 2016: Takeda Presents Analyses From Vedolizumab Data in Ulcerative Colitis at 2016 Digestive Disease Week Annual Meeting 78
    May 17, 2016: Protagonist Therapeutics to Present New Data on PTG-100 at Digestive Disease Week 2016 79
    Appendix 80
    Methodology 80
    Coverage 80
    Secondary Research 80
    Primary Research 80
    Expert Panel Validation 80
    Contact Us 80
    Disclaimer 81

    List of Tables

    Number of Products under Development for, H2 2016 8
    Number of Products under Development by Therapy Area, H2 2016 9
    Number of Products under Development by Indication, H2 2016 11
    Comparative Analysis by Late Stage Development, H2 2016 12
    Comparative Analysis by Early Stage Products, H2 2016 13
    Number of Products under Development by Companies, H2 2016 14
    Products under Development by Companies, H2 2016 15
    Products under Development by Companies, H2 2016 (Contd..1) 16
    Assessment by Monotherapy/Combination Products, H2 2016 17
    Number of Products by Stage and Mechanism of Action, H2 2016 19
    Number of Products by Stage and Route of Administration, H2 2016 21
    Number of Products by Stage and Molecule Type, H2 2016 23
    Pipeline by Antisense Therapeutics Limited, H2 2016 24
    Pipeline by Atox Bio Ltd., H2 2016 25
    Pipeline by Biogen Inc, H2 2016 26
    Pipeline by BioMAS Ltd., H2 2016 27
    Pipeline by Daiichi Sankyo Company, Limited, H2 2016 28
    Pipeline by EA Pharma Co Ltd, H2 2016 29
    Pipeline by Protagonist Therapeutics Inc., H2 2016 30
    Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 31
    Dormant Projects, H2 2016 60
    Dormant Projects (Contd..1), H2 2016 61
    Dormant Projects (Contd..2), H2 2016 62
    Dormant Projects (Contd..3), H2 2016 63
    Dormant Projects (Contd..4), H2 2016 64
    Discontinued Products, H2 2016 65

    List of Figures

    Number of Products under Development for, H2 2016 8
    Number of Products under Development by Therapy Area, H2 2016 9
    Number of Products under Development by Top 10 Indication, H2 2016 10
    Comparative Analysis by Late Stage Development, H2 2016 12
    Comparative Analysis by Early Stage Products, H2 2016 13
    Assessment by Monotherapy/Combination Products, H2 2016 17
    Number of Products by Mechanism of Actions, H2 2016 18
    Number of Products by Stage and Mechanism of Actions, H2 2016 18
    Number of Products by Routes of Administration, H2 2016 20
    Number of Products by Stage and Routes of Administration, H2 2016 20
    Number of Products by Molecule Types, H2 2016 22
    Number of Products by Stage and Molecule Type, H2 2016 22
    Antisense Therapeutics Limited
    Atox Bio Ltd.
    Biogen Inc
    BioMAS Ltd.
    Daiichi Sankyo Company, Limited
    EA Pharma Co Ltd
    Protagonist Therapeutics Inc.
    Takeda Pharmaceutical Company Limited

    Request for Sample

    Report Url https://www.reportsweb.com//integrin-alpha-4-pipeline-review-h2-2016&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//integrin-alpha-4-pipeline-review-h2-2016&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//integrin-alpha-4-pipeline-review-h2-2016&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments